Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
THOUSAND OAKS, Calif., Nov. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, Nov. 30, 2017, in Boston, beginning at 9:30 a.m. ET. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients su...
Source: Amgen News Release - November 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Launches The ENBREL Mini ™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users
Awarded Arthritis Foundation Ease of Use (SM) Commendation
THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients.
The AutoTouch™ reusable autoinjector has an ergonomic design that includes features that were designe...
Source: Amgen News Release - November 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Analyses Presented At AHA 2017 Show Repatha ® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks
Data Support Use of Repatha to Reduce Risk of Recurrent Cardiovascular Events in Patients With History of Multiple Heart Attacks
Additional Analysis Found That Patients With More Recent Heart Attacks Experienced Substantial Risk Reductions With Repatha
Repatha Benefit in Peripheral Artery Disease Patients Presented at AHA Scientific Sessions 2017 and Simultaneously Published in "Circulation"
THOUSAND OAKS, Calif., Nov. 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the additio...
Source: Amgen News Release - November 13, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate ® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins).
The posi...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval
THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 215, a biosimilar to Avastin® (bevacizumab). ABP 215 has been recommended for approval for the treatment of certain types of cancer, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum; i...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha ® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017
Late-Breaking Repatha Presentations Assess Impact on Peripheral Artery Disease and Heart Attack Patients
THOUSAND OAKS, Calif., Nov. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including analyses investigating the efficacy of Repatha in high-risk patients with peripheral artery disease (PAD) and those who have experienced a prior heart attack. In total, five distinct analyses from the Repatha cardiovascular outcomes study (FOURIER), including two accepted for late-breaker scientific sessions, will be presen...
Source: Amgen News Release - November 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
Parties to Collaborate on a New Generation Study 2, Assessing Whether Investigational Drug CNP520 Can Prevent or Delay the Symptoms of Alzheimer's Disease
Clinical Trial is Part of the Generation Program, Which Includes Cognitively Healthy People at Genetic Risk of Developing Alzheimer's Disease
Generation Study 2 Aims to Include a Broader High-Risk Population, as Compared to the Ongoing Generation Study 1
44 Million People Globally are Estimated to Have Alzheimer's Disease or a Related Dementia, With One New Case Diagnosed Every Three Seconds(1,2)
THOUSAND OAKS, Calif., Nov. 2, 2017 /PRNewswire/ -- Amgen (NASDA...
Source: Amgen News Release - November 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
$780 Million Payment to be Funded From Joint Venture's Existing Cash Holdings
Kyowa Hakko Kirin to Continue as Licensee in Asia
THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen.
Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the scope ...
Source: Amgen News Release - October 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
